摘要Objective:To evaluate the efficacy and safety of Shexiang Tongxin Dropping Pill(STDP)in treating stable angina patients with phlegm-heat and blood-stasis syndrome by exercise duration and metabolic equivalents.Methods:This multicenter,randomized,double-blind,placebo-controlled clinical trial enrolled stable angina patients with phlegm-heat and blood-stasis syndrome from 22 hospitals.They were randomized 1∶1 to STDP(35 mg/pill,6 pills per day)or placebo for 56 days.The primary outcome was the exercise duration and metabolic equivalents(METs)assessed by the standard Bruce exercise treadmill test after 56 days of treatment.The secondary outcomes included the total angina symptom score,Chinese medicine(CM)symptom scores,Seattle Angina Questionnaire(SAQ)scores,changes in ST-T on electrocardiogram and adverse events(AEs).Results:This trial enrolled 309 patients,including 155 and 154 in the STDP and placebo groups,respectively.STDP significantly prolonged exercise duration with an increase of 51.0 s,compared to a decrease of 12.0 s with placebo(change rate:-11.1％vs.3.2％,P＜0.01).The increase in METs was significantly greater in the STDP group than in the placebo group(change:-0.4 vs.0.0,change rate:-5.0％vs.0.0％,P＜0.01).The improvement of total angina symptom scores(25.0％vs.0.0％),CM symptom scores(38.7％vs.11.8％),reduction of nitroglycerin consumption(100.0％vs.11.3％),and all domains of SAQ,were significantly greater with STDP than placebo(all P＜0.01).The changes in Q-T intervals at 28 and 56 days from baseline were similar between the two groups(both P＞0.05).Twenty-five participants(16.3％)with STDP and 16(10.5％)with placebo experienced AEs(P=0.131),with no serious AEs observed.Conclusion:STDP could improve exercise tolerance in patients with stable angina and phlegm-heat and blood stasis syndrome,with a favorable safety profile.(Registration No.ChiCTR-IPR-15006020)